Life after hypomethylating agents in myelodysplastic syndrome: New strategies

Current Opinion in Hematology

Volumn 22, Issue 2, 2015, Pages 155-162

  Santini, Valeria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

hematopoietic stem cell transplant; kinase inhibitors; nucleoside analogs; signal transduction inhibitors; somatic mutations

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; ISOCITRATE DEHYDROGENASE 2; NEW DRUG; PROTEIN P53; ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE;

CANCER PROGNOSIS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; GENE MUTATION; GENETIC ANALYSIS; HEALTH STATUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SURVIVAL RATE; UMBILICAL CORD BLOOD; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; MORTALITY; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DNA METHYLATION; DNA MODIFICATION METHYLASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TREATMENT OUTCOME;

EID: 84923217986     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000117     Document Type: Review

References (64)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-232.
2. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-1803.
3. Craddock C, Quek L, Goardon N. Azacitidine fails to eradicate leukemic stem/ progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 2013; 27:1028-1036.
4. Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology Am Soc Hematol Educ Program 2012; 2012:65-73.
5. Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 2010; 116:1485-1494.
6. Santini V, Almeida A, Giagounidis A, et al. Efficacy and safety of lenalidomide (LEN) versus placebo (PBO) in RBC-transfusion dependent (TD) patients (Pts) with IPSS low/intermediate (Int-1)-risk myelodysplastic syndromes (MDS) without Del(5q) and unresponsive or refractory to erythropoiesis-stimulating agents (ESAs): results from a randomized phase 3 study (CC-5013-MDS-005). In: 56th American Society of Hematology meeting; San Francisco; 2014; abstract 409.
7. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29:3322-3327.
8. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010; 116:3830-3834.
9. Santini V, Prebet T, Fenaux P, et al. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res 2014; 38:1381-1391.
10. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30:3376-3382.
11. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122:3616-3627.
12. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28:241-247.
13. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014; 124:2705-2712.
14. Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 2014; 28:78-87.
15. Müller-Thomas C, Rudelius M, Rondak IC, et al. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica 2014; 99:e179-e181.
16. Bally C, Adès L, Renneville A, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res 2014; 38:751-755.
17. Tan P, Wei A, Mithraprabhu S, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J 2014; 4:e170.
18. Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol 2014; 32:1242-1248.
19. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): initial results of study 6898 of the New York Cancer Consortium. Blood 2013; 122:386.
20. Wang F, Travins J, Chen Y, et al. AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model. Blood 2013; 122:240.
21. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340:622-626.
22. Stein EM, Tallman MS, Pollyea DA, et al. An update of the clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH-2-mutant protein, in patients with IDH2-mutant positive advanced hematologic malignancies. In: 19th Congress of European Hematology Association; Milan; June 2014. Late breaking abstract 2434. www.ehaweb.org.
23. Jin J, Hu C, Yu M, Chen F, et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLoS One 2014; 9:e100206.
24. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64-69.
25. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118:6239-6246.
26. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119:3578-3584.
27. Hong DS, Kurzrock R, Naing A, et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs 2014; 32:436-44.
28. Bachegowda L, Gligich O, Mantzaris I, et al. Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol 2013; 6:50-61.
29. Gjertsen BT, Schöffski P. Discovery, development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2015; 29:11-19.
30. Döhner H, Lübbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 2014; 124:1426-1433.
31. Olnes MJ, Shenoy A, Weinstein B, et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res 2012; 36:982-989.
32. Silverman LR, Greenberg P, Raza A, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol 2014. [Epub ahead of print]
33. Komrokji RS, Raza A, Lancet JE, et al. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol 2013; 162:517-524.
34. Gupta P, Mulkey F, Hasserjian RP, et al. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 2013; 31:1311-1320.
35. Zhou L, McMahon C, Bhagat T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res 2011; 71:955-963.
36. Bhagat TD, Zhou L, Sokol L, et al. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood 2013; 121:2875-2881.
37. Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008; 112:3434-3443.
38. Ahnert JR, Baselga J, Calvo E, et al. First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment refractory malignant glioma. In: ASCO Annual Meeting; Chicago, IL; 2011; abstract 3011.
39. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 2014; 20:408-414.
40. Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol 2014; 165:870-882.
41. Platzbecker U, Germing U, Giagounidis A, et al. ACE-536 increases hemoglobin levels in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from a phase 2 study. Haematologica 2014; 99 (S1):500.
42. Iancu-Rubin C, Mosoyan G, Wang J, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 2013; 41:155-166.
43. Garcia-Manero G, Khoury HJ, Jabbour E, et al. A phase 1 study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate risk myelodysplastic syndromes. Clin Cancer Res 2014. [Epub ahead of print]
44. Komrokji RS, Padron E, Yu D, et al. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol 2014; 89:809-812.
45. Lainey E, Wolfromm A, Marie N, et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene 2013; 32:4331-4342.
46. Bryan J, Kantarjian H, Prescott H, et al. Clofarabine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs 2014; 23:255-263.
47. Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014; 28:1280-1288.
48. Coral S, Parisi G, Nicolay HJ, et al. Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide. Cancer Immunol Immunother 2013; 62:605-614.
49. Srivastava P, Paluch BE, Matsuzaki J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res 2014; 38:1332-1341.
50. Kantarjian HM, Jabbour E, Yee K, et al. First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML). Blood 2013; 122:497.
51. Oran B, Popat U, Andersson B, et al. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2013; 13 (Suppl 2):S282-S288.
52. Platzbecker U, Mufti G. Allogeneic stem cell transplantation in MDS: how? When? Best Pract Res Clin Haematol 2013; 26:421-429.
53. Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 2014; 20:1975-1981.
54. Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013; 31:2662-2670.
55. Armand P, Kim HT, Virtanen JM, et al. Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant 2014; 20:1248-1251.
56. Alessandrino EP, Della Porta MG, Pascutto C, et al. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? J Clin Oncol 2013; 31:2761-2762.
57. Yakoub-Agha I, Deeg J. Are hypomethylating agents replacing induction-type chemotherapy before allogeneic stem cell transplantation in patients with myelodysplastic syndrome? Biol Blood Marrow Transplant 2014; 20:1885-1890.
58. Damaj G, Mohty M, Robin M, et al. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Franc¸aise de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 2014; 20:1349-1355.
59. Sorror ML, Yi JC, Storer B, et al. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013; 121:2854-2863.
60. Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013; 98:208-216.
61. Onida F, Brand R, van Biezen A, et al. MDS subcommittee of the EBMT-CMWP. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica 2014; 99:1582-1590.
62. Della Porta MG, Alessandrino PE, Baciagalupo A, et al. Predictive factors for the out come of alllogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 2014; 123:2333-2342.
63. Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol 2014; 32:2691-2698.
64. Alessandrino EP, Porta MG, Malcovati L, et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol 2013; 88:581-588.